Global Clinical Trial Kits Market (2021 to 2028) - Featuring Charles River Laboratories, Almac and Alpha Laboratories Among Others

Dublin, Oct. 08, 2021 (GLOBE NEWSWIRE) -- The "Clinical Trial Kits Market Size, Share & Trends Analysis Report By Service (Kitting Solutions, Logistics), By Phase (Phase I, Phase II, Phase III, Phase IV), By Region, And Segment Forecasts, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.

The global clinical trial kits market size is anticipated to reach USD 2.5 billion by 2028, according to a new report by the publisher. The market is expected to expand at a CAGR of 8.5% from 2021 to 2028. The factors driving market expansion include globalization of clinical trials, increasing demand for remote services, and rising clinical trial complexity.

Remote clinical trial services are becoming increasingly essential in terms of patient retention, satisfaction, and safety. To enhance their capabilities, pharmaceutical companies have created a relationship with global logistics partners to provide direct-to-patient services. These services provide participants with the flexibility and convenience of participating in the trials while remaining at home.

COVID-19 pandemic has affected the market which resulted in slowing down the trial process. The COVID-19 pandemic is rapidly boosting advances in medical practices that allow people to connect with the healthcare system remotely. This effort of examining the patients at their homes has raised interest in at-home sample collection and testing. Such services offer convenience and minimize potential exposure to SARS-CoV-2.

Companies began to move to provide direct-to-consumer testing digital services. More aspects of the testing process, from test ordering to sample collection, are already making their way into patients' homes. Besides, regulatory authorities have instantly given sponsors guidelines to resolve issues that have arisen during ongoing clinical studies. Changes such as the use of telemedicine, the elimination of non-essential visits and laboratory assessments, as well as diagnostic testing and sample collection, have allowed many studies to continue while ensuring patient safety during the pandemic.

Clinical Trial Kits Market Report Highlights

• The logistics segment dominated the market and accounted for the largest revenue share of 54.9% in 2020. This is due to the increasing demand for services to simplify the logistics process in clinical trials

• The phase III segment dominated the market and accounted for the largest revenue share of 53.4% in 2020 as phase III trials require a large number of participants

• North America dominated the market in 2020 owing to favorable government support and the existence of a large number of companies offering innovative services in the U.S.

• In Asia Pacific, the market is projected to witness the highest CAGR of 9.9% over the forecast period as the region is continuously growing in terms of clinical trials due to the vast population and developing technology

Key Topics Covered:

Chapter 1 Methodology and Scope

Chapter 2 Executive Summary

Chapter 3 Clinical Trial Kits Market: Variables, Trends, & Scope
3.1 Market Lineage Outlook
3.1.1 Parent market outlook
3.1.2 Ancillary market outlook
3.2 Penetration & Growth Prospect Mapping
3.3 Market Dynamics
3.3.1 Market Driver Analysis
3.3.1.1 Globalization of clinical trials
3.3.1.2 Increasing demand for remote services
3.3.1.3 Rising clinical trial complexity
3.3.2 Market Restraint Analysis
3.3.2.1 Varying regulations in countries
3.4 Clinical Trial Kits Market Analysis Tools
3.4.1 Porter's five forces analysis
3.4.2 PESTEL analysis
3.4.3 Major deals & strategic alliances
3.4.3.1 Acquisitions
3.4.3.2 Partnerships
3.4.3.3 Expansion
3.4.3.4 Product launch
3.4.3.5 Collaboration
3.5 Clinical Trial Kits Market: Total Addressable Market (TAM) Analysis
3.5.1 Market Overview

Chapter 4 Covid-19 Impact
4.1 COVID-19 Impact on the market
4.2 COVID-19 Impact on the logistics
4.3 COVID-19 Pandemic Impact on Clinical Trial Activity
4.3.1 Obstacles in clinical trials
4.3.2 Disrupted clinical trials
4.3.2.1 Companies with Phase I trial disruption
4.3.2.2 Companies with Phase 2 trial disruption
4.3.2.3 Companies with Phase 3 trial disruption

Chapter 5 Clinical Trial Kits Market: Service Segment Analysis
5.1 Clinical Trial Kits: Market Share Analysis, 2020 & 2028
5.2 Kitting Solutions
5.2.1 Kitting solutions market, 2016 - 2028 (USD Million)
5.2.2 Drug Kits
5.2.2.1 Drug kits market, 2016 - 2028 (USD Million)
5.2.3 Sample Collection Kits
5.2.3.1 Sample collection kits market, 2016 - 2028 (USD Million)
5.3 Logistics
5.3.1 Logistics market, 2016 - 2028 (USD Million)
5.3.2 Transportation
5.3.2.1 Transportation market, 2016 - 2028 (USD Million)
5.3.3 Warehousing & storage
5.3.3.1 Warehousing & storage market, 2016 - 2028 (USD Million)
5.3.4 Others
5.3.4.1 Others market, 2016 - 2028 (USD Million)

Chapter 6 Clinical Trial Kits Market: Phase Segment Analysis
6.1 Clinical Trial Kits: Market Share Analysis, 2020 & 2028
6.2 Phase I
6.2.1 Phase I Market, 2016 - 2028 (USD Million)
6.3 Phase II
6.3.1 Phase II market, 2016 - 2028 (USD Million)
6.4 Phase III
6.4.1 Phase III market, 2016 - 2028 (USD Million)
6.5 Phase IV
6.5.1 Phase IV market, 2016 - 2028 (USD Million)

Chapter 7 Clinical Trial Kits Market: Regional Analysis

Chapter 8 Competitive Landscape
8.1 Company Profiles
8.1.1 Brooks Life Science
8.1.1.1 Company overview
8.1.1.2 Financial performance
8.1.1.3 Service benchmarking
8.1.1.4 Strategy initiatives
8.1.2 Q2 solutions
8.1.2.1 Company overview
8.1.2.2 Financial performance
8.1.2.3 Service benchmarking
8.1.2.4 Strategy initiatives
8.1.3 Patheon (Thermo Fisher Scientific Inc)
8.1.3.1 Company overview
8.1.3.2 Financial performance
8.1.3.3 ServicebBenchmarking
8.1.4 Labcorp Drug Development
8.1.4.1 Company overview
8.1.4.2 financial performance
8.1.4.3 Service benchmarking
8.1.4.4 Strategy initiatives
8.1.5 Charles River Laboratories
8.1.5.1 Company overview
8.1.5.2 Financial performance
8.1.5.3 Service benchmarking
8.1.6 LAbConnect
8.1.6.1 Company overview
8.1.6.2 Service Benchmarking
8.1.6.3 Strategy initiatives
8.1.7 Almac group
8.1.7.1 Company overview
8.1.7.2 Service benchmarking
8.1.7.3 Strategy initiatives
8.1.8 Precision Medicine Group
8.1.8.1 Company overview
8.1.8.2 Service benchmarking
8.1.8.3 Strategic initiatives
8.1.9 Cerba research
8.1.9.1 Company overview
8.1.9.2 Service benchmarking
8.1.10 Alpha laboratories
8.1.10.1 Company overview
8.1.10.2 Service benchmarking
8.1.11 Marken a UPS company
8.1.11.1 Company overview
8.1.11.2 Service benchmarking
8.1.11.3 Strategy initiatives
8.1.12 Clinigen
8.1.12.1 Company overview
8.1.12.2 Financial performance
8.1.12.3 Service benchmarking
8.1.12.4 Strategy initiatives

For more information about this report visit https://www.researchandmarkets.com/r/lbz1ty

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900